Company: LNAI
Filing Date: 2025-07-10
Form Type: SCHEDULE 13D/A
Source: 0001214659-25-010280
Chunk: 0

Company: Lunai Bioworks Inc.
Filing Date: 2025-07-10
Form: SCHEDULE 13D/A
Chunk 0
---
ROS") and (ii) 12,438,431 shares owned by Gumrukcu, of which Wittekind shares voting and dispositive power through a power of attorney dated June 24, 2022. Pursuant to an order of the United States District Court for the District of Vermont dated October 27, 2023, the 12,438,431 shares owned by Gumrukcu are subject to a writ of attachment to secure the plaintiffs' claim in The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123). (3) The percentage ownership disclosed in Row 13 is based upon (i) 172,7118,569 shares outstanding as of May 13, 2025, as disclosed in the Issuer's Form 10-Q filed with the Commission on May 15, 2025 plus (ii) 53,600,000 shares to be issued on or before July 11, 2025 upon conversion of convertible notes as reported in the Issuer's Form 8-K filed with the Commission on July 9, 2025.

| SCHEDULE 13D |

| Item 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Security and Issuer                                                                                                                                                           |
| (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Common Stock, par value $0.0001 per share                                                                                                                                     |
| (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Renovaro Inc.                                                                                                                                                                 |
| (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | CENTURY CITY MEDICAL PLAZA, 2080 CENTURY CITY EAST, SUITE 906 LOS ANGELES,                                                                                                    
 CALIFORNIA                                                                                                                                                                    
 , 90067.                                                                                                                                                                      |
| Item 1 Comment:This Amendment No. 21 amends the Schedule 13D filed by Weird Science LLC, a California limited liability company ("Weird Science") and William Anderson Wittekind, a member and manager of Weird Science ("Wittekind") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Renovaro Inc. (the "Issuer") received by Weird Science pursuant to that certain Agreement and Plan of Merger dated January 12, 2018 (the "Merger Agreement") by and among the Issuer (then known as DanDrit BioTech USA, Inc.), DanDrit